The Australian Securities Exchange (ASX) has put a pause on the trading of shares belonging to Cann Group Limited (ASX: CAN), an Australian cannabis-producing firm, following the surfacing of alarming signals regarding the company’s financial health. The move comes after the company’s auditor raised significant concerns about Cann Group’s ability to continue its operations amidst substantial financial losses.

Cann Group disclosed an unsettling operating loss of AU$14.3 million for the first half of the fiscal year, which concluded on December 31, 2023. This financial haemorrhage has cast doubts on the firm’s sustainability and its ability to fund future activities.

Further complicating Cann Group’s trajectory is the apprehension expressed by its auditor, William Buck Audit (Vic) Pty. The auditor’s report underscored uncertainty about the company’s potential to secure enough funding that would enable it to operate as a going concern in the subsequent twelve months. This statement hints at the possibility of Cann Group not being able to meet its financial obligations without securing additional capital or financing.

In a response that underscores the severity of its financial predicament, Cann Group managed to negotiate a reprieve with its lender, National Australia Bank (NAB). The agreement involves a one-year deferment of the principal loan repayment, pushing the due date from May 2024 to May 2025. The loan, amounting to an onerous AU$49 million, represents a significant liability on the firm’s balance sheet which, if left unaddressed, could drastically affect its liquidity and overall financial stability.

Despite the grim news on its operational losses and financial condition, Cann Group’s sales figures portray a more nuanced picture of its business activities. For the first half of 2023, the company reported sales amounting to AU$8.5 million, which indicates a significant 46% uptick compared to the corresponding period in the previous year. This growth in revenue is primarily attributed to the surge in orders for medical cannabis flower, alongside contract packing revenue and consignment sales, suggesting that while the company faces substantial challenges, there are still areas of the business that are experiencing notable growth.

 

Top Australian Brokers

 

The current halt in trading is not just a temporary measure for Cann Group but a harbinger of the underlying struggles within the emergent cannabis industry in Australia, where regulatory frameworks and market acceptance are still in development stages. Investors and stakeholders are closely monitoring the situation, anticipating the company’s next move to navigate through the financially straitened circumstances it finds itself ensnared in.